Amneal PharmaceuticalsAMRX +0.71%61 Forward Dividend Yield % is 0.00% as of Jul. 07, 2026. GuruFocus rates AMRX with a GF Score™ of 61/100 and a GF Value™ of $7.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 507 Drug Manufacturers companies, Amneal Pharmaceuticals ranks worse than 197238.46% on this metric.
As of today (2026-07-07), the Forward Annual Dividend Yield of Amneal Pharmaceuticals is 0.00%.
As of today (2026-07-07), the Trailing Annual Dividend Yield of Amneal Pharmaceuticals is 0.00%.
AMRX's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.03 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Amneal Pharmaceuticals Forward Dividend Yield % Related Terms
AMRX vs INDV, KNSA, LQDA: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Amneal Pharmaceuticals (AMRX) has a Forward Dividend Yield % of 0.00% as of Jul. 07, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Amneal Pharmaceuticals and its competitors. According to the industry distribution chart, Amneal Pharmaceuticals ranks #999999 out of 507 companies in the Drug Manufacturers industry.
Is Amneal Pharmaceuticals' Forward Dividend Yield % too high?
Amneal Pharmaceuticals' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Amneal Pharmaceuticals ranks #999999 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amneal Pharmaceuticals has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Forward Dividend Yield % compare to INDV and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #999999 out of 507 companies for Forward Dividend Yield %. This places Amneal Pharmaceuticals in the lower half of its industry. The industry median Forward Dividend Yield % is 2.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.03, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Amneal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.58, compared to a current price of $17.07 — trading 125.2% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Amneal Pharmaceuticals' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Forward Dividend Yield % is 0.00% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $17.07 is trading 125.2% above its estimated GF Value™ of $7.58.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
Forward Dividend Yield %: 0.00%
GF Value™: $7.58 vs. price of $17.07 (125.2% above fair value)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
61GF Score
Get the complete analysis for AMRX
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 